68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Feb 18, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help doctors perform surgery for medullary thyroid cancer (MTC) using a special imaging technique called 68Ga-TCR-FAPI PET/CT. This method helps identify how far the cancer has spread, which can guide surgeons in making better decisions during the operation. The main goal of the study is to see if this imaging technique can help lower the levels of a hormone called calcitonin one month after surgery, which indicates how well the treatment worked.

To participate in this trial, individuals must be between 18 and 75 years old and have been diagnosed with MTC, meaning they need surgery to treat their cancer. They should be in good overall health and not have serious organ problems. Participants will undergo the imaging test to guide their surgery and will need to understand and agree to be part of the study. It's important to note that individuals with allergies to imaging agents, who are pregnant or breastfeeding, or who don’t have a need for surgery, will not be eligible to join. This trial is currently recruiting participants, and it offers a potential new approach to improve outcomes for those facing this type of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 75 years；
• • Diagnosed with MTC and have surgical indication based on preliminary evaluation; the tumor may be newly diagnosed or previously treated;
• • Expected survival of at least 12 weeks;
• • No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection;
• • Be willing and able to understand the research content and provide written informed consent/assent for the trial.
• Exclusion Criteria:
• • Have a history of imaging agent allergies;
• • Does not meet the PET-CT scan sedation requirements, or has contraindications for PET-CT examination;
• • Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial;
• • No surgical indication (i.e., no measurable disease, unresectable disease, or significant present of distant metastasis), refusing surgery or 68Ga-TCR-FAPI PET/CT-guided surgery.